Merck reportedly in talks to buy drugmaker for more than double Friday’s price

Merck
MRK,
+0.18%
is in talks to buy cancer drugmaker Harpoon Therapeutics
HARP,
-1.49%
for about $700 million, or $23 per share, Bloomberg News reported, citing people familiar with the matter. Merck didn’t comment to Bloomberg, the report said, while Harpoon didn’t respond. Shares of Harpoon closed Friday at $10.55.